329 related articles for article (PubMed ID: 22340912)
1. New directions in anticoagulation.
Alpert JS
Am J Med; 2012 Mar; 125(3):217-8. PubMed ID: 22340912
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Harrington AR; Armstrong EP; Nolan PE; Malone DC
Stroke; 2013 Jun; 44(6):1676-81. PubMed ID: 23549134
[TBL] [Abstract][Full Text] [Related]
4. Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
Fanikos J
J Med Econ; 2013 Oct; 16(10):1190-2. PubMed ID: 23919663
[No Abstract] [Full Text] [Related]
5. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Berman JP; Halperin JL
Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
[TBL] [Abstract][Full Text] [Related]
6. A new era for anticoagulation in atrial fibrillation.
Mega JL
N Engl J Med; 2011 Sep; 365(11):1052-4. PubMed ID: 21870977
[No Abstract] [Full Text] [Related]
7. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
8. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Contractor T; Levin V; Martinez MW; Marchlinski FE
Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669
[TBL] [Abstract][Full Text] [Related]
9. The novel oral anticoagulants: an update for the interventional radiologist.
Crockett MT; Moynagh MR; Kavanagh EC
AJR Am J Roentgenol; 2012 Sep; 199(3):W376-9. PubMed ID: 22915429
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
Verhoef TI; Redekop WK; Hasrat F; de Boer A; Maitland-van der Zee AH
Am J Cardiovasc Drugs; 2014 Dec; 14(6):451-62. PubMed ID: 25326294
[TBL] [Abstract][Full Text] [Related]
11. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
Ahrens I; Lip GY; Peter K
Thromb Haemost; 2011 Apr; 105(4):574-8. PubMed ID: 21225102
[No Abstract] [Full Text] [Related]
12. Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
Cairns JA; Weitz JI
Am Heart J; 2015 Jan; 169(1):1-3. PubMed ID: 25497240
[No Abstract] [Full Text] [Related]
13. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
14. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
[TBL] [Abstract][Full Text] [Related]
15. Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Amin A; Stokes M; Makenbaeva D; Wiederkehr D; Wu N; Lawrence JH
J Med Econ; 2014 Nov; 17(11):771-81. PubMed ID: 25133458
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Lenchus JD
Hosp Pract (1995); 2013 Feb; 41(1):49-60. PubMed ID: 23466967
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulating obese patients in the modern era.
Patel JP; Roberts LN; Arya R
Br J Haematol; 2011 Oct; 155(2):137-49. PubMed ID: 21848880
[TBL] [Abstract][Full Text] [Related]
19. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
[TBL] [Abstract][Full Text] [Related]
20. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Rognoni C; Marchetti M; Quaglini S; Liberato NL
Clin Drug Investig; 2014 Jan; 34(1):9-17. PubMed ID: 24135964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
